Testo-E Testosterone Enanthate 300 mg/ml

• Testo E 300 – Testosterone Enanthate (Royal Pharmaceuticals)
• Category: Injectable Testosterone Ester (Research Only)
• Brand: Royal Pharmaceuticals
• Concentration: 300 mg/ml testosterone enanthate
• Packing: 10 1 ml ampoules
• Origin: United Kingdom
• Research Notice: For laboratory, analytical and collector use only. Not for human or veterinary administration.

What Is Testosterone Enanthate?

Testosterone enanthate is a long-chain ester of testosterone (testosterone 17-heptanoate).

It acts as a pro-drug, slowly releasing free testosterone after ester cleavage.

This extended-release profile makes TE a widely studied reference androgen ester for:

• Androgen receptor signalling research
• Gene-expression and endocrine modelling
• Anti-doping method validation (LC-MS/MS, GC-MS panels)
• Pharmacokinetic modelling of depot testosterone esters

This profile describes the compound strictly for research and analytical purposes — not as a therapy, supplement or performance enhancer.

Mechanism of Action

1. Pro-Drug Conversion

Esterases cleave the heptanoate chain following depot formation, releasing bioactive testosterone.

The resulting testosterone binds nuclear androgen receptors in muscle, bone and reproductive tissues.

2. Androgen Receptor Effects

• Upregulation of androgen-responsive genes
• Increased protein synthesis and nitrogen retention
• Stimulation of erythropoiesis
• Support of secondary sexual characteristics

3. Metabolic Pathways

5- reduction dihydrotestosterone (DHT)

Aromatisation estradiol (E2)

These pathways contribute to the overall androgenic/anabolic behaviour of TE in research models.

4. Depot Pharmacokinetics

The enanthate ester slows testosterone release, with an elimination half-life of approximately 4–5 days in clinical references — longer than propionate, shorter than undecanoate.

Research Applications

• Reference steroid for mass-spectrometry calibration
• Long-acting androgen model in PK studies
• Endocrine pathway modelling
• In-vitro androgen receptor assays
• WADA and IOC anti-doping research

Potential Research-Level Observations

• Sustained androgen receptor activation over multiple days
• Stable testosterone exposure curve under controlled conditions
• Elevated erythropoiesis markers
• Predictable metabolite profile for analytical detection

Safety Profile & Known Risks (Class Effects)

Androgenic

• Acne and seborrhoea
• Accelerated androgenic alopecia in predisposed individuals
• Virilisation if exposed in females

Cardiometabolic

• HDL reduction and LDL increase
• Possible rise in blood pressure
• Increased hematocrit / polycythaemia

Endocrine Suppression

• Reduced LH/FSH
• Lower endogenous testosterone production
• Compromised fertility in prolonged exposure models

Hepatic & Systemic

• Altered liver enzyme markers
• Psychological variability: irritability or low mood in some subjects
• Injection-site discomfort or irritation

Safety classifications for TE often list reproductive toxicity and possible carcinogenicity; provided for technical documentation only.

Compliance & Legal Status

Controlled substance in many jurisdictions.

WADA S1 – Anabolic Agents: prohibited at all times.

Any laboratory handling must comply with institutional biosafety standards.

Not a supplement, medication or consumer product.

Technical Data Table

Intended Use

Research, analytical, reference standard

For research and analytical use only. Not for human or veterinary administration.